Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma.

ABSTRACT:

Background

Given the significant advancements in the management of hepatocellular carcinoma (HCC) and the emergence of novel treatment approaches, establishing reliable predictors has become crucial for optimizing patient selection and therapeutic sequencing in HCC. In this study, we aimed to investigate the prognostic factors and treatment efficacy associated with lenvatinib-based therapy.

Methods

We retrospectively enrolled 53 patients receiving lenvatinib monotherapy, and 19 patients receiving lenvatinib plus immune checkpoint inhibitor combination therapy as their first-line systemic treatment for unresectable HCC at a single medical center. We employed univariate and multivariate Cox regression analyses to ascertain the factors influencing survival in these cohorts.

SUBMITTER: Wang HW 

PROVIDER: S-EPMC11565097 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature